PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.
Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.
LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.
Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q3
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.
DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.
Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.
Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2
Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Inogen (INGN) saw growth in revenues within its Rental segment in Q2.
The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services
Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss
by Zacks Equity Research
Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.
What Makes PerkinElmer (PKI) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.
LabCorp (LH) Banks on Covance Amid Testing Volume Pressure
by Zacks Equity Research
LabCorp's (LH) COVID-19 related research too has been progressing well.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.
Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.
Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.
Wall Street is Northbound Defying All Concerns: 5 Top Picks
by Nalak Das
A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.
IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise
by Zacks Equity Research
IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.
Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract
by Zacks Equity Research
Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.
DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States were solid in Q2.
NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates
by Zacks Equity Research
NextGen (NXGN) benefited from its Recurring segment in Q1.
Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises
by Zacks Equity Research
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.